GI Innovation Inc. Logo

GI Innovation Inc.

Develops fusion protein biologics for oncology, allergic, and metabolic diseases.

358570 | KO

Overview

Corporate Details

ISIN(s):
KR7358570000
LEI:
Country:
South Korea
Address:
서울특별시 송파구 송파대로 167, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

GI Innovation Inc. is a biopharmaceutical company engaged in the research and development of next-generation immunotherapies. The company utilizes its proprietary GI-SMART™ platform to create innovative fusion protein-based biologics. Its development pipeline targets diseases with high unmet medical needs, focusing on therapeutic areas such as immuno-oncology (GI-101, GI-10N), allergic and fibrotic diseases (GI-301, GI-30N), and metabolic diseases (GI-20N). Operating under a "Science, Strategy, Speed" philosophy, GI Innovation advances its drug candidates through well-structured translational research and strategic collaborations with global pharmaceutical companies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청) (건강한 성인 및 암 생존자를 대상으로 한 GI102 요법의 노화 관련 생…
Korean 8.2 KB
2025-09-05 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획변경승인신청) (GI101 단일 요법 또는 펨브롤리주맙 또는 렌바티닙 병용 요법의 안…
Korean 13.0 KB
2025-09-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-09-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB
2025-09-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.5 KB
2025-09-04 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 957.2 KB
2025-08-29 00:00
Share Issue/Capital Change
전환주식의전환청구권행사 (전환우선주)
Korean 15.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-08-05 00:00
Share Issue/Capital Change
주요사항보고서(전환사채매수선택권행사자지정)
Korean 23.8 KB
2025-07-10 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-07-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.5 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB
2025-06-26 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 604.9 KB
2025-06-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB
2025-06-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB

Automate Your Workflow. Get a real-time feed of all GI Innovation Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GI Innovation Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GI Innovation Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS
Ernexa Therapeutics Inc. Logo
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America
ERNA
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France
ERYP
Esperion Therapeutics, Inc. Logo
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America
ESPR
ESSA Pharma Inc. Logo
Develops novel small molecule drugs to treat castration-resistant prostate cancer.
United States of America
EPIX
Estrella Immunopharma, Inc. Logo
Clinical-stage biopharma developing ARTEMIS® T-cell therapies for cancer & autoimmune disease.
United States of America
ESLA
Eton Pharmaceuticals, Inc. Logo
Develops and commercializes innovative treatments for rare pediatric diseases.
United States of America
ETON
EuBiologics Co., Ltd. Logo
Develops vaccines for global public health and provides biopharmaceutical CRMO services.
South Korea
206650
EUPRAXIA PHARMACEUTICALS INC. Logo
Developing targeted, extended-release therapies for GI and musculoskeletal diseases.
United States of America
EPRX
EuroAPI Logo
Global manufacturer of APIs and CDMO services for human and animal health partners worldwide.
France
EAPI

Talk to a Data Expert

Have a question? We'll get back to you promptly.